A daily pill combined with chemotherapy has produced striking results in patients with advanced pancreatic cancer, with tumours becoming undetectable in about one in 12 patients and shrinking in more than 60 per cent of those treated, according to new clinical trial findings.
The drug, called daraxonrasib, was tested in 61 patients whose pancreatic cancer had spread to other parts of the body. Researchers found that tumours shrank or disappeared in 60.7 per cent of patients, while 8.2 per cent showed no detectable signs of cancer on scans.
The findings, presented on Friday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, offer fresh hope for treating one of the deadliest forms of cancer.
According to the European Organisation for Research and Treatment of Cancer (EORTC), the treatment also stopped the disease from progressing in 90.2 per cent of patients. The median period before the cancer worsened or patients died was 12.8 months.
Dr Wungki Park, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York who led the research, described the findings as “a massive, massive breakthrough”.
“In about one in 12 patients, it [the cancer] completely disappeared,” he told the Press Association, according to British broadcaster LBC.
Why the findings matter